BofA raised the firm’s price target on Progyny (PGNY) to $30 from $25 and keeps a Buy rating on the shares after President Trump signed an executive order aimed at protecting and expanding access to in vitro fertilization. If there is federal legislation that preempts state law and mandates IVF coverage for carriers, it could increase the demand for Progyny’s solutions and government sponsored policy recommendations could also catalyze Progyny’s current government customers and prospects to add benefits over time, the analyst tells investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny price target raised to $25 from $21 at BofA
- Progyny announces acquisition of BenefitBump, terms not disclosed
- Progyny Strengthens Leadership with New Director Appointment
- Progyny appoints Morris to board of directors
- Progyny sees Q4 results slightly above guidance ranges provided in November